Publications by authors named "Matthew S McKinney"
Targeting tumor-specific molecular alterations has shown significant clinical benefit. Molecular tumor boards (MTBs) connect cancer patients with personalized treatments and clinical trials. However, rural cancer centers often have limited access to MTB expertise.
View Article and Find Full Text PDFArticle Synopsis
- Comprehensive genomic profiling (CGP) is commonly used to guide treatment for solid tumors and myeloid neoplasms, but its effectiveness for lymphoid and histiocytic cancers is less established.
- In a study of 105 CGP samples from patients with non-myeloid hematologic malignancies, 88% showed pathogenic mutations, with 72% of patients having mutations that could influence their treatment or prognosis.
- The study found that CGP led to a significant change in management for 22% of patients, particularly in cases where resistance variants were identified, affecting treatment decisions in nearly 70% of those cases.
Article Synopsis
- This study looks at patients with mantle cell lymphoma (MCL) to understand their different experiences and predict their outcomes better.
- It involves a big group of hospitals in North America and looks at 586 MCL cases from 2000 to 2012 to find important patterns in treatment and results.
- The researchers discovered that certain treatments and factors, like using stem cell transplants and checking for specific proteins, are really important to know how well patients will do over time.
Background: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) assessed efficacy and safety of parsaclisib monotherapy in patients with R/R follicular lymphoma (FL).
Methods: Patients ≥18 years of age with histologically confirmed R/R FL (grade 1-3a) and prior treatment with ≥2 systemic therapies received parsaclisib 20 mg once daily (QD) for 8 weeks then parsaclisib 20 mg once weekly (weekly dosing group [WG]) or parsaclisib 20 mg QD for 8 weeks then parsaclisib 2.
Unlabelled: Comprehensive genomic profiling to inform targeted therapy selection is a central part of oncology care. However, the volume and complexity of alterations uncovered through genomic profiling make it difficult for oncologists to choose the most appropriate therapy for their patients. Here, we present a solution to this problem, The Molecular Registry of Tumors (MRT) and our Molecular Tumor Board (MTB).
View Article and Find Full Text PDFMerkel cell polyomavirus (MCPyV) is a DNA virus whose pathogenic mechanisms in Merkel cell carcinoma (MCC) are still being unraveled. Emerging reports of an association between MCPyV and chronic lymphocytic lymphoma (CLL) have begun to broaden our understanding of the oncogenic mechanisms of this virus and the known association between these 2 malignancies. Herein, we report a case of MCC demonstrating a B-cell immunophenotype arising in a patient with CLL being treated with rituximab.
View Article and Find Full Text PDFPurpose: The phosphoinositide 3-kinase (PI3K) pathway is known to play an active role in many malignancies. The role of PI3K inhibition in the treatment of lymphomas has not been fully delineated. We sought to identify a role for therapeutic PI3K inhibition across a range of B-cell lymphomas.
View Article and Find Full Text PDF